Humoral anti-KLH responses in cancer patients treated with dendritic cell-based immunotherapy are dictated by different vaccination parameters

PURPOSE: Keyhole limpet hemocyanin (KLH) attracts biomedical interest because of its remarkable immunostimulatory properties. Currently, KLH is used as vaccine adjuvant, carrier protein for haptens and as local treatment for bladder cancer. Since a quantitative human anti-KLH assay is lacking, it ha...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Aarntzen, Erik H. J. G., de Vries, I. Jolanda M., Göertz, Joop H., Beldhuis-Valkis, Marjo, Brouwers, Huberdina M. L. M., van de Rakt, Mandy W. M. M., van der Molen, Renate G., Punt, Cornelis J. A., Adema, Gosse J., Tacken, Paul J., Joosten, Irma, Jacobs, Joannes F. M.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Springer-Verlag 2012
Soggetti:
Original Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3493659/
https://ncbi.nlm.nih.gov/pubmed/22527252
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00262-012-1263-z
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi